Amylyx Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 2/4
Amylyx Pharmaceuticals CEO'su Josh Cohen, Jan2013 tarihinde atandı, in görev süresi 11.83 yıldır. in toplam yıllık tazminatı $ 7.42M olup, şirket hissesi ve opsiyonları dahil olmak üzere 8.4% maaş ve 91.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 4.26% ine doğrudan sahiptir ve bu hisseler $ 15.27M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.9 yıl ve 3.8 yıldır.
Anahtar bilgiler
Josh Cohen
İcra Kurulu Başkanı
US$7.4m
Toplam tazminat
| CEO maaş yüzdesi | 8.4% |
| CEO görev süresi | 11.8yrs |
| CEO sahipliği | 4.3% |
| Yönetim ortalama görev süresi | 3.9yrs |
| Yönetim Kurulu ortalama görev süresi | 3.8yrs |
Son yönetim güncellemeleri
Recent updates
Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along
Nov 25There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise
Nov 04
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry
Sep 18Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
Jun 25Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop
Apr 25Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically
Mar 12An ALS Drug Fails Again
Mar 09Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications
Feb 23Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues
Feb 23Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper
Nov 10Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Sep 24This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year
May 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Apr 20Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates
Mar 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans
Dec 19Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share
Oct 07Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis
Sep 30Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing
Sep 08Amylyx plunges 28% after FDA briefing documents on ALS drug
Sep 02We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate
Aug 29Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.01
Aug 11Amylyx Pharmaceuticals says ALS treatment Albrioza now available in Canada
Jul 29CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$259m |
| Jun 30 2024 | n/a | n/a | -US$166m |
| Mar 31 2024 | n/a | n/a | -US$71m |
| Dec 31 2023 | US$7m | US$621k | US$49m |
| Sep 30 2023 | n/a | n/a | US$2m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$149m |
| Dec 31 2022 | US$7m | US$539k | -US$198m |
| Sep 30 2022 | n/a | n/a | -US$184m |
| Jun 30 2022 | n/a | n/a | -US$153m |
| Mar 31 2022 | n/a | n/a | -US$121m |
| Dec 31 2021 | US$1m | US$418k | -US$88m |
| Sep 30 2021 | n/a | n/a | -US$68m |
| Dec 31 2020 | US$671k | US$370k | -US$42m |
Tazminat ve Piyasa: Josh 'nin toplam tazminatı ($USD 7.42M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.16M ).
Tazminat ve Kazançlar: Josh şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Josh Cohen (32 yo)
11.8yrs
Görev süresi
US$7,418,169
Tazminat
Mr. Joshua B. Cohen also known as Josh, co-founded Amylyx Pharmaceuticals, Inc. in 2013 and has been its Co-Chief Executive Officer and Director since January 2014. Mr. Cohen served as Chairman of the Boar...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 11.8yrs | US$7.42m | 4.26% $ 15.3m | |
| Co-Founder | 11.8yrs | US$7.42m | 4.2% $ 15.1m | |
| Chief Financial Officer | 3.8yrs | US$3.51m | 0.14% $ 509.8k | |
| Chief Legal Officer & General Counsel | 2.8yrs | US$3.01m | 0.21% $ 752.4k | |
| Chief Medical Officer | less than a year | US$2.37m | 0.030% $ 108.2k | |
| Chief Technical Operations Officer | no data | Veri yok | Veri yok | |
| Head of Investor Relations & Communications | no data | Veri yok | Veri yok | |
| Head of Global Marketing | 3.9yrs | Veri yok | Veri yok | |
| Chief Human Resources Officer | less than a year | Veri yok | Veri yok | |
| Head of Canada & GM | 3.6yrs | Veri yok | Veri yok | |
| Head of Global Market Access | 3.9yrs | Veri yok | Veri yok | |
| Global Head of Regulatory Affairs | 4.3yrs | Veri yok | Veri yok |
3.9yrs
Ortalama Görev Süresi
53yo
Ortalama Yaş
Deneyimli Yönetim: AMLX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.9 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 10.8yrs | US$7.42m | 4.26% $ 15.3m | |
| Co-Founder | 10.8yrs | US$7.42m | 4.2% $ 15.1m | |
| Company Secretary & Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Special Advisor & Member of Advisory Board | 3.8yrs | US$51.24k | Veri yok | |
| Independent Chairman of the Board | 9.8yrs | US$385.07k | 1.26% $ 4.5m | |
| Chairman of The Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Board Observer & Advisor | 7.3yrs | Veri yok | Veri yok | |
| Independent Director | 1.7yrs | US$681.15k | 0.081% $ 289.8k | |
| Independent Director | 3.4yrs | US$348.59k | 0.0073% $ 26.3k | |
| Independent Director | less than a year | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 3.7yrs | US$342.12k | 0.0058% $ 20.8k |
3.8yrs
Ortalama Görev Süresi
63yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: AMLX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).